Logo

GNLX

Genelux Corporation

GNLX

Genelux Corporation • NASDAQ
$5.56 ▼ -0.54% (-0.03)
Market Cap $211.57 M
52w High $8.54
52w Low $1.99
Dividend Yield 0%
P/E -6.32
Volume 82.67K
Outstanding Shares 38.05M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $8.194M ▲ $-7.95M ▼ 0% $-0.21 ▼ $-7.806M ▼
Q2-2025 $0 $7.649M ▼ $-7.456M ▲ 0% $-0.2 ▲ $-7.313M ▲
Q1-2025 $0 $7.816M ▼ $-7.492M ▲ 0% $-0.21 ▲ $-7.677M ▲
Q4-2024 $0 $9.748M ▲ $-8.976M ▼ 0% $-0.27 ▼ $-8.749M ▼
Q3-2024 $0 $6.941M $-6.467M 0% $-0.19 $-6.243M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $20.915M ▼ $24.987M ▼ $6.396M ▼ $18.591M ▼
Q2-2025 $27.972M ▼ $32.247M ▼ $8.349M ▼ $23.898M ▼
Q1-2025 $35.102M ▲ $38.985M ▲ $9.139M ▲ $29.846M ▲
Q4-2024 $30.895M ▼ $34.716M ▼ $8.442M ▲ $26.274M ▼
Q3-2024 $34.057M $40.27M $7.179M $33.091M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.95M ▼ $-6.575M ▲ $4.721M ▲ $0 ▼ $-1.854M ▲ $-7.092M ▲
Q2-2025 $-7.456M ▲ $-7.059M ▼ $-2.653M ▼ $52K ▼ $-9.66M ▼ $-7.174M ▼
Q1-2025 $-7.492M ▲ $-5.435M ▼ $3.509M ▼ $9.567M ▲ $7.641M ▲ $-5.465M ▼
Q4-2024 $-8.976M ▼ $-4.302M ▲ $6.674M ▲ $91K ▲ $2.463M ▲ $-4.398M ▲
Q3-2024 $-6.467M $-5.748M $3.992M $0 $-1.756M $-5.775M

Five-Year Company Overview

Income Statement

Income Statement Genelux is still in the classic clinical‑stage biotech phase: it has essentially no product revenue yet and runs a steady operating loss as it funds trials and research. Losses have grown a bit as the company scaled up, and earnings per share remain clearly negative. This pattern is normal for an early‑stage biotech but means the story is entirely about future trial success rather than current profitability.

Balance Sheet

Balance Sheet The balance sheet is small and fairly simple. Assets are limited, with cash making up a meaningful share, and there is no notable financial debt outstanding anymore. Equity has recently moved from negative to positive, which is an improvement, but the overall capital base is still thin. The company is financially lean and dependent on continued access to capital as it advances its pipeline.

Cash Flow

Cash Flow Cash flows are consistently negative from day‑to‑day operations, reflecting spending on clinical trials and overhead without any offsetting product sales. There is essentially no heavy investment in physical assets, so cash use is primarily research and development plus general expenses. Overall, the business is currently a cash‑consuming enterprise and will likely need periodic funding to keep programs moving forward.

Competitive Edge

Competitive Edge Genelux operates in a crowded and technically demanding field—immuno‑oncology and oncolytic viruses—but it has some differentiating features. Its lead asset, Olvi‑Vec, is relatively advanced in development with a pivotal trial underway in a difficult ovarian cancer setting. The ability to potentially re‑sensitize tumors to chemotherapy and deliver the therapy systemically are important points of differentiation. The proprietary CHOICE platform, a growing library of engineered viruses, fast‑track status, and regional partnerships add to its competitive footing. At the same time, the company faces intense competition from larger, better‑funded players and the usual clinical and regulatory risks of oncology drug development.

Innovation and R&D

Innovation and R&D Innovation is the core of Genelux’s value proposition. The CHOICE platform allows rapid design and testing of many virus variants, giving a pipeline‑engine rather than a single‑asset story. Olvi‑Vec’s three‑part mechanism—direct tumor killing, immune activation, and reshaping of the tumor environment—is designed to tackle hard‑to‑treat solid tumors and possibly make existing treatments work better again. Collaborations such as V2ACT, which pairs Olvi‑Vec with adoptive T‑cell therapy, show a willingness to pursue complex, next‑generation combinations. The main risk is that most of this innovation is still being validated in the clinic; success depends on strong, reproducible trial data over the next few years.

Summary

Genelux is a young, research‑driven biotech with no meaningful revenue yet, ongoing losses, and negative cash generation—typical for a company at this stage. Its balance sheet is modest but currently clean, with cash on hand and no notable debt, though it will likely rely on future financing. The investment case centers almost entirely on the scientific and clinical prospects of Olvi‑Vec and the broader CHOICE platform. If pivotal and mid‑stage trials read out well, the company could move from a single‑asset bet toward a broader oncolytic virus franchise. However, clinical, regulatory, funding, and competitive risks remain high, and outcomes are uncertain until more data from ongoing trials become available.

NEWS

November 5, 2025 · 4:20 PM UTC

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

Read more